Mode
Text Size
Log in / Sign up

Compensated cirrhosis

Part of Cirrhosis

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Compensated cirrhosis

9 trials tracked for Compensated cirrhosis: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 278 citations.

9Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 5 Phase 2 3 Phase 1 1
  1. Phase 3 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Completed · 278 cited
  2. Phase 3 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis Completed · 162 cited
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis Completed · 39 cited
  4. Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Completed
  5. Phase 3 A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis Completed
  6. Phase 2 Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) Completed
Show 3 more trials
  1. Phase 2 A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) Completed
  2. Phase 2 An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis Completed
  3. Phase 1 An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Compensated cirrhosis: what the trials found

Several multi-drug regimens demonstrated high rates of sustained virologic response (SVR12) in clinical trials. Ombitasvir/Paritaprevir/Ritonavir achieved SVR12 rates of 94.1% 2 and 100% 3, with no instances of on-treatment failure or post-treatment relapse reported in these cohorts.

Combination therapies including ABT-493/ABT-530 4 and ABT-450/r/ABT-267, ABT-333 6 also showed high efficacy. Specifically, the ABT-493/ABT-530 regimen achieved a 99.3% SVR12 rate 4, while the ABT-450/r/ABT-267, ABT-333 regimens reached SVR12 rates of 91.8% and 96.5%, respectively 6.

In a study evaluating Obeticholic acid (10 mg), the number of participants showing improvement in fibrosis by at least one stage without worsening of NASH was 31, 33, and 37 across groups, which did not reach statistical significance (p=0.6172) 5.

Recent results — preliminary, needs further review

  • Seladelpar showed a 33.3% rate of treatment-related adverse events (TEAEs) and a 40.0% rate of Grade 3 or 4 TEAEs in a Phase 1 trial 1.
  • Nitazoxanide 500mg BID showed a statistically significant increase in Lumican Fractional Synthesis Rate (FSR) from baseline to the end of treatment (p=0.0039), with a 15.46% increase 8.
  • ABT-493 showed SVR12 rates ranging from 87.5% to 100% across multiple study arms in a Phase 2 trial 9.

For the clinician treating this condition

  • Multiple combination regimens (Ombitasvir/Paritaprevir/Ritonavir, ABT-493/ABT-530, and ABT-450/r/ABT-267/ABT-333) have demonstrated high SVR12 rates in established trials.
  • Obeticholic acid showed no statistically significant improvement in fibrosis stages compared to controls 5.

AI synthesis of 8 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cirrhosis

Related studies from across the Cirrhosis family.

Exercise programs improve muscle mass and physical performance indicators in patients with liver cirrhosis
Rheumatology Meta-analysis
Exercise programs improve muscle mass and physical performance indicators in patients with liver cirrhosis Exercise improves muscle strength in cirrhosis patients
This meta-analysis of 16 studies involving 942 patients found that exercise interventions significantly improved 6-min walk distance, thigh …
Exercise boosts muscle mass and walking ability in people with cirrhosis and muscle loss, a new analysis finds.
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes
This systematic review and exploratory meta-analysis evaluated incident cirrhosis or composite serious liver events among adults with type 2…
A new analysis suggests GLP-1 receptor agonists might reduce serious liver events compared to DPP-4 inhibitors for adults with type 2 diabet…
Hepatologist-led palliative care matches specialist care for cirrhosis and cancer patients
Gastroenterology RCT
Hepatologist-led palliative care matches specialist care for cirrhosis and cancer patients Trained liver doctors provided care that matched specialists for patients with serious liver disease
A US trial found hepatologist-delivered palliative care noninferior to specialist care for improving quality of life in advanced liver disea…
Patients with advanced liver disease saw similar quality of life improvements when cared for by trained liver doctors versus specialists. Bo…
Endovascular interventions reduce rebleeding risk versus endoscopic cyanoacrylate injection in gastric variceal hemorrhage
Gastroenterology Meta-analysis
Endovascular interventions reduce rebleeding risk versus endoscopic cyanoacrylate injection in gastric variceal hemorrhage Endovascular procedures reduce rebleeding risk for cirrhosis patients compared to injection therapy
This individual patient data meta-analysis compares endovascular interventions with endoscopic cyanoacrylate injection for gastric variceal …
A meta-analysis of 1,240 patients found endovascular procedures significantly lower rebleeding rates than injection therapy, though they car…
Antimicrobial resistance reaches 33.3% in cirrhosis patients with bacterial infections across global settings
Gastroenterology Meta-analysis
Antimicrobial resistance reaches 33.3% in cirrhosis patients with bacterial infections across global settings Antimicrobial resistance is rising in cirrhosis patients worldwide
This systematic review and meta-analysis examines bacterial infections in 35,180 adult patients with cirrhosis globally. The analysis report…
A global analysis of 35,180 patients with cirrhosis shows rising antimicrobial resistance and varying mortality risks.
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B
Allergy & Immunology Sys. Review
Review of antiviral and immunotherapeutic strategies for chronic hepatitis B New antiviral strategies show promise for chronic hepatitis B infection
This narrative review synthesizes evidence on antiviral and immunotherapeutic strategies for chronic hepatitis B. The authors highlight func…
A review of new treatments suggests combination therapies may offer future value for managing chronic hepatitis B, cirrhosis, and liver canc…
Patient Buddy App reduced avoidable readmissions in cirrhosis inpatients compared to standard of care
Gastroenterology RCT
Patient Buddy App reduced avoidable readmissions in cirrhosis inpatients compared to standard of care App helps cirrhosis patients avoid hospital readmission
This randomized clinical trial enrolled 464 subjects (232 dyads) with cirrhosis in a multicenter setting.
A smartphone app cut avoidable hospital readmissions in half for cirrhosis patients, a new trial shows.
Five ACLF diagnostic models and prognostic scores identified markedly different proportions of patients at risk of 28-day mortality in a cohort study
Gastroenterology Cohort
Five ACLF diagnostic models and prognostic scores identified markedly different proportions of patients at risk of 28-day mortality in a cohort study Two new models find the sickest liver patients faster than old tools
This cohort study evaluated five acute-on-chronic liver failure (ACLF) diagnostic models and prognostic scores in 3,370 patients from the CO…
Two new scoring systems find the most dangerous liver failure patients better than older tools, potentially saving lives by catching risk ea…
Systematic review shows high rates of fibrosis and cirrhosis in children with Pi*ZZ alpha-1 antitrypsin deficiency
Gastroenterology Meta-analysis
Systematic review shows high rates of fibrosis and cirrhosis in children with Pi*ZZ alpha-1 antitrypsin deficiency 1 in 4 children with A1AT deficiency develop cirrhosis
This systematic review and meta-analysis examined children with confirmed Pi*ZZ alpha-1 antitrypsin deficiency to assess liver outcomes.
New analysis finds 41% of children with A1AT deficiency have liver fibrosis and 17% have cirrhosis.
Systematic review finds weak link between atypical antipsychotics and MASLD in youth
Gastroenterology Meta-analysis
Systematic review finds weak link between atypical antipsychotics and MASLD in youth Atypical antipsychotics show a small link to liver disease in young patients
This systematic review and meta-analysis of 3 studies examined the association between atypical antipsychotics and metabolic dysfunction-ass…
A review of three studies found a small link between atypical antipsychotics and liver disease in children, but the evidence is limited.
L-taurine shows no overall fatigue benefit in decompensated cirrhosis but may help non-anemic patients
Gastroenterology RCT
L-taurine shows no overall fatigue benefit in decompensated cirrhosis but may help non-anemic patients Taurine for cirrhosis fatigue fails overall but helps one group
This randomized controlled trial in 220 adults with decompensated cirrhosis found no significant difference in fatigue scores with L-taurine…
Taurine did not reduce fatigue in most cirrhosis patients, but those without anemia saw meaningful improvement, suggesting a targeted approa…
Systematic review links periodontitis to NAFLD progression and HCC risk
Gastroenterology Sys. Review
Systematic review links periodontitis to NAFLD progression and HCC risk Your Mouth Could Be Harming Your Liver—Here’s What to Do
This systematic review finds that periodontitis and oral pathogens like F.
You brush your teeth every day. You might floss sometimes.